| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S89517-5mg |
≥98% | ￥2790.00 |
货期：3-5天 | - | - | - | - |
|
S89517-10mg |
≥98% | ￥4490.00 |
货期：3-5天 | - | - | - | - |
|
S89517-25mg |
≥98% | ￥10600.00 |
货期：3-5天 | - | - | - | - |
|
S89517-100mg |
≥98% | ￥25400.00 |
货期：3-5天 | - | - | - | - |
|
| 产品描述： | Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and community-acquired pneumonia and skin structure infections. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体外研究： | Avarofloxacin demonstrates an antibacterial effect against numerous Gram-positive bacteria (mean MIC90: 0.12 mg/L) [2]. Avarofloxacin has the potential for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections | ||||||||||||||||||||
| 参考文献： | 1. Jones TM, et al. Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. 2. Kocsis B, et al. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016 May 23;15(1):34. 3. Farrell DJ, et al. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother. 2011 Jul;55(7):3631-4. |
||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京